Melissa officinalis — lemon balm — is a member of the mint family that has been used since antiquity for its calming properties and its effect on memory and concentration. In medieval Europe, it was a primary ingredient in Carmelite water — a herbal preparation supposedly formulated by nuns at the Carmelite monastery in Paris that was used for centuries as a memory tonic and mood enhancer. Modern research has substantiated many of these traditional uses, and recent studies have established that lemon balm has measurable effects on the GABAergic system, on acetylcholine esterase, and on mood and cognitive performance in adults.
The GABAergic Mechanism
Like benzodiazepines, lemon balm’s active constituents (primarily rosmarinic acid, flavonoids, and volatile oils) enhance the activity of the GABA-A receptor — the primary inhibitory receptor in the brain. Unlike benzodiazepines, which bind directly to a specific site on the receptor, lemon balm’s constituents appear to modulate GABAergic activity through a different mechanism — possibly by increasing the availability of GABA itself. The practical consequence is that lemon balm produces measurable anxiolytic effects without sedation, cognitive impairment, or the development of tolerance that characterises benzodiazepines.
Lemon Balm and Alzheimer’s: The Acetylcholinesterase Inhibition Effect
One of the most intriguing mechanisms of lemon balm is its inhibition of acetylcholinesterase (AChE) — the enzyme that breaks down acetylcholine in the synaptic cleft. This is the same mechanism as the pharmaceutical AChE inhibitors (donepezil, rivastigmine, galantamine) used in Alzheimer’s disease treatment. In vitro studies show that Melissa officinalis extract inhibits AChE with a potency comparable to pharmaceutical AChE inhibitors. A double-blind RCT in 42 patients with mild to moderate Alzheimer’s disease found that lemon balm at 500mg twice daily significantly improved cognitive function and reduced agitation compared to placebo over 16 weeks.
Lemon Balm for Sleep and Insomnia
Lemon balm’s combination of anxiolytic and mild sedative properties makes it particularly useful for insomnia — especially the type driven by anxiety and rumination. A randomised controlled trial in 100 menopausal women with insomnia found that a combination of lemon balm and valerian (450mg of lemon balm, 500mg of valerian) significantly improved sleep quality and reduced insomnia symptoms compared to placebo, with efficacy comparable to 5mg of temazepam but with a better side-effect profile. For sleep applications, lemon balm at 400-800mg of standardised extract is typically used in combination with valerian root at 400-800mg.
Practical Dosing and Interactions
The evidence-based dose for cognitive enhancement and anxiety reduction is 300-600mg of standardised Melissa officinalis extract (minimum 3% rosmarinic acid) 2-3 times daily. For insomnia, 400-800mg of standardised extract is taken 30-60 minutes before bedtime, often in combination with valerian. Lemon balm is generally well-tolerated, with rare reports of GI discomfort or mild headache. It should not be combined with sedatives, benzodiazepines, or cholinesterase inhibitors without medical supervision due to the theoretical risk of excessive sedation.
How GABA Works in the Nervous System
GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the mammalian central nervous system. Where glutamate promotes neuronal firing and excitation, GABA suppresses it — maintaining the balance between excitation and inhibition that allows the brain to function without constant seizure-like overactivation. GABAergic neurons make up approximately 20-30% of all neurons in the brain, and GABA receptors are present on virtually every neuronal type, making GABA the universal modulator of neural circuit activity. When GABA binds to GABA-A receptors, it opens chloride channels, hyperpolarising the neuron and making it less likely to fire. This is why GABA-promoting substances — whether pharmaceutical (benzodiazepines, barbiturates) or nutritional — tend to have calming, anxiolytic, and sometimes sedative effects.
The Gut-Brain GABA Axis
A substantial proportion of the body GABA is produced by gut bacteria, particularly Lactobacillus and Bifidobacterium species. These bacteria produce GABA via the glutamate decarboxylase pathway, and this GABA acts locally on the enteric nervous system, modulating gut motility, secretion, and pain signalling. There is bidirectional communication between gut-derived GABA and brain GABA function — the so-called gut-brain axis. Certain probiotic strains marketed as psychobiotics have been shown to increase GABA production and reduce anxiety behaviours in animal models, and preliminary human data suggests similar anxiolytic effects from specific multi-strain probiotics.
Why Oral GABA May Not Cross the Blood-Brain Barrier
A contentious area in nutritional neuroscience is whether orally consumed GABA can cross the blood-brain barrier. The evidence suggests that at typical supplemental doses (250-1000mg), systemic GABA does not meaningfully cross into the CNS. However, some studies show physiological effects from oral GABA — such as increased alpha brain wave activity on EEG and reduced cortisol — even if direct BBB penetration is minimal. Proposed mechanisms include vagal nerve activation from gut GABA receptors, or effects on peripheral GABA receptors that indirectly influence CNS function via neuroendocrine pathways.
Leave a Reply